Home » Newsletters » BioWorld Science

BioWorld Science

May 7, 2015

View Archived Issues

Baxter's Ross River virus vaccine well tolerated in phase III study

Shire updates progress of first quarter 2015

Turnstone Biologics combines oncolytic and vaccine activity in single viral vector

Antroquinonol assigned FDA orphan drug designation for acute myeloid leukemia

Lenalidomide gains another U.S. orphan drug designation

Cancer Targeted Technology receives grant to develop PET imaging agent for prostate cancer

Tobira Therapeutics completes merger with Regado Biosciences

Graspa expanded access program cleared to continue by DSMB

Acacia Pharma posts results from phase II study of APD-403 for CINV

ZIOPHARM starts phase I trial of Ad-RTS-hIL-12 plus veledimex in glioma and glioblastoma

Global Enterprises Group launches personalized medicine developer Predictive Therapeutics

Bellicum in-licenses rights to TCR therapies against two tumor antigens

Basilea's pan-RAF kinase inhibitor BAL-3833 enters phase I study

Replicor discloses phase II data for REP-2139

A novel isoquinolone sulfonamide derivative for wet AMD

NCX-667 reduces IOP in different animal models

DHA derivative confers protection against neovascularization and retinopathy

Tadalafil given orphan designation in the U.S. for Duchenne muscular dystrophy

Lokon Pharma receives U.S. orphan drug label for cancer vaccine

New phase II trial of MM-141 for pancreatic cancer in biomarker-selected patients

Kineta releases topline phase Ib results on dalazatide in plaque psoriasis

E.U. marketing submission for GSK-2696273 gene therapy to treat ADA-SCID

Roche and Genentech divulge NMDA receptor modulators

Eisai reports TLR7 and TLR8 antagonists

Janssen describes ROR-gamma-t receptor modulators

Bayer Schering Pharma develops adenosine A2B receptor antagonists

MJFF and Prothena join forces to accelerate discovery of biomarkers for Parkinson's disease

Teva completes acquisition of Auspex

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...